Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535753 | 0.83 | LMNA (0.44) | ALDH1A1LMNAMAPK1HPGDSMN1; SMN2 | |
| SCHEMBL6673886 | 0.83 | ALDH1A1 (0.51) | ALDH1A1LMNAGAAMAPK1PGR | |
| SCHEMBL7541533 | 0.82 | L3MBTL1 (0.41) | ALDH1A1LMNAMAPK1CA1CA2 | |
| SCHEMBL6087565 | 0.82 | ALDH1A1 (0.62) | ALDH1A1LMNAGAAMAPK1PGR | |
| SCHEMBL8104251 | 0.81 | ALDH1A1 (0.60) | ALDH1A1LMNAGAAMAPK1PGR | |
| SCHEMBL7533431 | 0.81 | PKM (0.47) | LMNAGAACA1CA2POLB | |
| SCHEMBL6673947 | 0.77 | ALDH1A1 (0.56) | ALDH1A1LMNAGAAMAPK1PGR | |
| SCHEMBL6676861 | 0.77 | ALDH1A1 (0.56) | ALDH1A1LMNAGAAMAPK1PGR | |
| SCHEMBL7535604 | 0.77 | ALDH1A1 (0.50) | ALDH1A1LMNAGAAMAPK1PGR | |
| SCHEMBL6678322 | 0.77 | ALDH1A1 (0.50) | ALDH1A1LMNAGAAMAPK1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | ALDH1A1 1173/4885LMNA 2006/4885GAA 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.